Market Overview

UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval

Related BIIB
Is Illumina Worth Adding To Your Portfolio?
The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley
Don't Panic Over Recent Tech Turmoil (Fox Business)

In a report published Thursday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB), and raised the price target from $187.00 to $200.00.

In the report, Baral noted, “Reiterate BUY, increasing target to $200 on approval of Tecfidera (Tec), BIIB's new blockbuster potential oral MS drug with sparkling clean label. BIIB guidance implies strong confidence in the Tec launch. We have confidence in the initial phase of launch on high levels of community patient warehousing.We see long-term value and blockbuster potential in Tec, Tysabri and the hemophilia franchise. Our $200 price target is DCF-based.”

Biogen Idec closed on Wednesday at $182.68.

Latest Ratings for BIIB

DateFirmActionFromTo
Nov 2014Credit SuisseMaintainsOutperform
Oct 2014CitigroupMaintainsBuy
Oct 2014BairdUpgradesNeutralOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (BIIB)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional